John M. Siebert - 22 Feb 2022 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 Feb 2022, 20:26:11 UTC
Prior SEC filing
23 Feb 2022
Next SEC filing
24 Feb 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

John M. Siebert filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 24 Feb 2022.

Key facts

  • This page summarizes John M. Siebert's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 24 Feb 2022, 20:26.

Change

  • Previous filing in this sequence was filed on 23 Feb 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
80,175
Date
22 Feb 2022
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+6,847
Change %
Price
$0.000000
Shares after
6,847
Date
22 Feb 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,847
Exercise price
$32.20
SUPN transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+3,882
Change %
Price
$0.000000
Shares after
3,882
Date
22 Feb 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,882
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F2

These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .